Yun Zhong is ranked #2394 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

WEDB

Yun Zhong

Q: How accurate are Yun Zhong's stock ratings?

About 37% of Yun's ratings were profitable over a one-year hold, with an average return of +6.9% per rating, measured by 13Foresight from historical prices.

Wedbush

Wall Street Analyst

★★☆☆☆

#2394

on 13Foresight · ranked by our own returns

37%

Success Rate

+6.9%

Average Return

28 of 76 calls profitable · +1.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 37% of Yun Zhong's ratings turned a profit when each position was held for 1 year — averaging +6.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

160 Buy 10 Hold 0 Sell

Yun's Stock Coverage 29 ratings · 2026-10-01

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
WVE Wave Life Sciences	Sep 30, 2026	BUY	Strong Buy +453.3% avg upside 29 analysts	$12.00 226.14% Upside	·	·
CAMP CAMP4 Therapeutics Corporation	Sep 29, 2026	BUY	Strong Buy +146.3% avg upside 9 analysts	$8.00 97.50% Upside	+0.0%	·
RZLT Rezolute	Sep 25, 2026	BUY	Strong Buy +170.1% avg upside 14 analysts	$6.00 42.65% Upside	+0.0%	·
ASND Ascendis Pharma	Sep 16, 2026	BUY	Strong Buy +24.9% avg upside 26 analysts	$327.00 42.38% Upside	-7.8%	·
RCKT Rocket Pharmaceuticals	Sep 15, 2026	BUY	Buy +518.0% avg upside 30 analysts	$15.00 462.92% Upside	-23.9%	·
BNTC Benitec Biopharma	Sep 15, 2026	BUY	Strong Buy +151.0% avg upside 14 analysts	$17.00 70.08% Upside	-13.2%	·
IRD Opus Genetics	Sep 09, 2026	BUY	Strong Buy +144.5% avg upside 25 analysts	$13.00 168.04% Upside	-15.5%	·
SRPT Sarepta Therapeutics	Sep 08, 2026	BUY	Buy +233.0% avg upside 50 analysts	$35.00 89.82% Upside	-10.8%	·
PTGX Protagonist Therapeutics	Aug 31, 2026	BUY	Strong Buy -14.8% avg upside 19 analysts	$173.00 21.94% Upside	-4.9%	·
BMRN BioMarin Pharmaceutical	Aug 18, 2026	BUY	Strong Buy +60.7% avg upside 52 analysts	$94.00 55.19% Upside	-11.1%	·
SGMT Sagimet Biosciences, Inc. Class A	Aug 11, 2026	BUY	Strong Buy +188.0% avg upside 17 analysts	$28.00 184.80% Upside	-2.0%	·
KLRS Kalaris Therapeutics	Aug 11, 2026	BUY	Buy +339.9% avg upside 13 analysts	$17.00 476.30% Upside	-22.7%	·
MLTX MoonLake Immunotherapeutics	Aug 10, 2026	BUY	Strong Buy +160.8% avg upside 20 analysts	$34.00 186.98% Upside	-30.5%	·
VYGR Voyager Therapeutics	Aug 07, 2026	BUY	Strong Buy +434.3% avg upside 23 analysts	$8.00 196.27% Upside	-17.4%	·
MNKD MannKind	Aug 06, 2026	BUY	Buy +79.0% avg upside 22 analysts	$8.00 99.54% Upside	-15.4%	·
KROS Keros Therapeutics	Aug 04, 2026	HOLD	Strong Buy +110.0% avg upside 21 analysts	$16.00 38.79% Upside	+12.7%	·
PASG Passage Bio	Apr 21, 2026	HOLD	Buy +289.7% avg upside 14 analysts	$8.00 78.51% Upside	-19.1%	·
TSHA Taysha Gene Therapies	Mar 30, 2023	HOLD	Strong Buy +191.4% avg upside 22 analysts	—	+296.4%	·
AVXL Anavex Life Sciences	Mar 30, 2023	BUY	Strong Buy +1108.8% avg upside 9 analysts	$28.00 1314.15% Upside	-38.8%	·
QURE uniQure	Mar 28, 2023	BUY	Strong Buy +143.6% avg upside 30 analysts	$38.00 55.84% Upside	-74.1%	·
TECX Tectonic Therapeutic	Mar 23, 2023	BUY	Strong Buy +134.4% avg upside 24 analysts	$4.00 82.76% Downside	+43.8%	·
RNAC Cartesian Therapeutics	Mar 21, 2023	BUY	Strong Buy +330.6% avg upside 19 analysts	$8.00 9.63% Upside	-44.1%	·
LENZ LENZ Therapeutics	Mar 21, 2023	HOLD	Buy +435.8% avg upside 17 analysts	—	+93.9%	·
MREO Mereo Biopharma Group Plc	Mar 21, 2023	BUY	Strong Buy +878.3% avg upside 11 analysts	$4.00 912.71% Upside	+242.2%	·
DNTH Dianthus Therapeutics	Jan 26, 2023	HOLD	Strong Buy +14.1% avg upside 31 analysts	—	+154.0%	·
MRKR Marker Therapeutics	May 12, 2020	BUY	Strong Buy +1250.1% avg upside 9 analysts	$10.00 834.58% Upside	-8.5%	·
ELOX Eloxx Pharmaceuticals	Feb 04, 2020	BUY	Strong Buy +136.5% avg upside 12 analysts	$14.00 8.30% Downside	·	·
DNLI Denali Therapeutics	Nov 12, 2018	BUY	Strong Buy +87.5% avg upside 24 analysts	—	-9.9%	·
SMMT Summit Therapeutics	Jun 28, 2018	HOLD	Strong Buy +73.2% avg upside 29 analysts	—	-46.9%	·

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Yun Zhong — Frequently Asked Questions

How accurate are Yun Zhong's stock ratings?

Based on the calls 13Foresight could measure, about 37% of Yun's ratings were profitable over a one-year hold, with an average return of +6.9% per rating, or +1.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Yun ranked on 13Foresight?

Yun Zhong is currently ranked #2394 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Yun cover?

Yun most recently has ratings on WVE, CAMP, RZLT, ASND, RCKT, BNTC, IRD, SRPT, PTGX, BMRN, SGMT, KLRS and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Yun Zhong

Rating Distribution

Welcome to 13Foresight!